Sobi Presents Clinical Study Updates at ISTH Congress in Washington.

Sobi will present 10 clinical study updates at the ISTH Congress in Washington. The updates include new data for avatrombopag in children with ITP, surgery outcomes using efanesoctocog alfa, and long-term haemophilia studies. The company's R&D and Medical Affairs teams will showcase the data to further advance treatments for rare blood conditions.

Sobi (STO: SOBI), a global biopharma company, will present a total of ten clinical study updates at the upcoming International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington, scheduled from June 21 to 25. The company's Research and Development (R&D) and Medical Affairs teams will showcase a range of data aimed at advancing treatments for rare blood conditions, including immune thrombocytopenia (ITP) and haemophilia.

The presentations will cover a variety of topics, including new data for avatrombopag in children with ITP, surgery outcomes using efanesoctocog alfa, and long-term haemophilia studies. The company's Chief Medical Officer, Lydia Abad-Franch, MD, emphasized the importance of attending ISTH for collaboration and knowledge sharing to further advance treatments for these conditions [1].

Among the highlights, the company will present data on avatrombopag, a drug indicated for the treatment of primary chronic ITP in adults who are refractory to other treatments. The presentations will include abstracts on the drug's efficacy and safety in children with ITP, as well as real-world outcomes stratified by prior TPO-RA exposure [1].

Additionally, Sobi will showcase results from the XTEND clinical program, which focuses on efanesoctocog alfa, a treatment for haemophilia A. The program includes presentations on major surgical outcomes, treatment of bleeding episodes in children, and joint health outcomes in adults and adolescents [1].

Sobi's collaboration with Novartis on the development and commercialization of Alprolix and Elocta/Eloctate is also expected to be highlighted. Alprolix, a treatment for haemophilia B, has shown promising results in long-term extension studies [1].

The presentations at ISTH 2025 are a significant milestone for Sobi, demonstrating its commitment to advancing treatments for rare blood disorders. The company's ability to present extensive clinical data underscores its dedication to improving patient outcomes and addressing unmet medical needs.

References:
[1] Sobi will showcase extensive research and clinical outcomes at ISTH 2025. https://www.prnewswire.com/news-releases/sobi-will-showcase-extensive-research-and-clinical-outcomes-at-isth-2025-302486857.html